Taiho Pharmaceutical establishes subsidiary

The Japanese company Taiho Pharmaceutical has established a subsidiary in Zug in the form of Taiho Oncology Europe GmbH. The new company will concentrate on clinical development and distribution activities in Europe, as detailed in a press release, while additionally focusing on the development of drugs to treat cancer. Taiho Oncology Europe GmbH will also be responsible for commercialization activities tied to futibatinib, a cancer drug which is still under development.

With its new subsidiary, Taiho Pharmaceutical is advancing its global growth plans, the press release explains further. In addition to Taiho Oncology Europe GmbH in Zug, the European business of the Japanese group is also being supported by the US subsidiary Taiho Oncology, Inc.

For its part, Taiho Pharmaceutical is owned by Otsuka Holdings Co., a pharmaceutical group headquartered in Tokyo that specializes in research and development activities. At the moment, the group’s companies are involved in advancing the development of new drug candidates in the areas of oncology, allergies, immunology and urology.